S4:E184 David provides The Weekly Update in Venture and then Paul interviews Adovate CEO William Stilley about their innovative drug development platform to exploit adenosine receptors involved in multiple major diseases. He explains their strategy of focusing on a single drug candidate with favorable physiochemical characteristics and distribution kinetics that treats a common disease with few to no side effects. They will be initiating their phase II trial of their candidate drug this year and if successful, will plan to sell the drug to a major Pharma company. (interview recorded 8.6.25)The Data Center Power post by Tyler Norris, a Power Systems expert, in his Power & Policy NewsletterFollow David on X at https://x.com/DGRollingSouth Connect On LinkedIn with David at https://www.linkedin.com/in/davidgrisell/ Follow Paul on X at https://x.com/PalmettoAngel Connect On LinkedIn with Paul at https://www.linkedin.com/in/paulclarkprivateequity/ We invite your feedback and suggestions at www.ventureinthesouth.com or email [email protected].

Ver todos los episodios